Åsa Mellgren1, Miriam Karlsson2, Marie Karlsson3, Martin Lagging4, Rune Wejstål5, Heléne Norder6. 1. Clinic of Infectious Diseases, South Älvsborg Hospital, Borås, Sweden. Electronic address: asa.mellgren@vgregion.se. 2. Clinic of Infectious Diseases, South Älvsborg Hospital, Borås, Sweden. Electronic address: Miriam.ec.karlsson@vgregion.se. 3. Department of Infectious Medicine/Virology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Sweden. Electronic address: marie.karlsson.2@gu.se. 4. Department of Infectious Medicine/Virology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Sweden. Electronic address: martin.lagging@medfack.gu.se. 5. Department of Infectious Diseases, University of Gothenburg, Gothenburg, Sweden. Electronic address: rune.weijstal@vgregion.se. 6. Department of Infectious Medicine/Virology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Sweden. Electronic address: helene.norder@gu.se.
Abstract
BACKGROUND: Hepatitis E virus (HEV) genotype 3 is endemic in Europe. Superinfection with HEV in patients with underlying chronic liver disease can cause hepatic decompensation leading to increased morbidity and mortality. OBJECTIVES: The prevalence of anti-HEV antibodies was investigated in 204 patients with chronic hepatitis C virus (HCV) infection and different stages of fibrosis. STUDY DESIGN: Sera were analyzed for anti-HEV IgG, IgM and HEV RNA. RESULTS: The median age of the patients was 55 years (IQR 40-62 years); 126 (62%) were men. Ninety-eight (48%) patients had a METAVIR fibrosis stage F2 or higher. The prevalence of anti-HEV IgG was 30% (62/204), which was significantly higher than among Swedish blood donors (17%, p<0.01). The prevalence of anti-HEV antibodies was associated with higher age (OR 1.08 (1.05-1.11); p<0.01). It was also higher for patients with a prior history of blood transfusion (48%) as compared to intravenous drug use (IDU; 26%) as the risk factor for acquisition of the HCV infection (OR 2.72 (1.2-6.19); p<0.02). The prevalence of anti-HEV IgG was also significantly higher in patients with significant fibrosis, i.e. ≥F2 (38%; OR 2.04 (1.11-3.76); p=0.02) and/or neoplasm (72%; OR 7.27 (2.46-21.44); p<0.01). CONCLUSIONS: When adjusted for age, the prevalence of anti-HEV antibodies was significantly higher in patients with previous or current malignant liver disease compared to blood donors. The lack of significant correlation between HCV and HEV infections indicate low level of transmission of HEV by IDU. HEV infections warrant more attention, especially in patients with preexisting liver disease.
BACKGROUND:Hepatitis E virus (HEV) genotype 3 is endemic in Europe. Superinfection with HEV in patients with underlying chronic liver disease can cause hepatic decompensation leading to increased morbidity and mortality. OBJECTIVES: The prevalence of anti-HEV antibodies was investigated in 204 patients with chronic hepatitis C virus (HCV) infection and different stages of fibrosis. STUDY DESIGN: Sera were analyzed for anti-HEV IgG, IgM and HEV RNA. RESULTS: The median age of the patients was 55 years (IQR 40-62 years); 126 (62%) were men. Ninety-eight (48%) patients had a METAVIR fibrosis stage F2 or higher. The prevalence of anti-HEV IgG was 30% (62/204), which was significantly higher than among Swedish blood donors (17%, p<0.01). The prevalence of anti-HEV antibodies was associated with higher age (OR 1.08 (1.05-1.11); p<0.01). It was also higher for patients with a prior history of blood transfusion (48%) as compared to intravenous drug use (IDU; 26%) as the risk factor for acquisition of the HCV infection (OR 2.72 (1.2-6.19); p<0.02). The prevalence of anti-HEV IgG was also significantly higher in patients with significant fibrosis, i.e. ≥F2 (38%; OR 2.04 (1.11-3.76); p=0.02) and/or neoplasm (72%; OR 7.27 (2.46-21.44); p<0.01). CONCLUSIONS: When adjusted for age, the prevalence of anti-HEV antibodies was significantly higher in patients with previous or current malignant liver disease compared to blood donors. The lack of significant correlation between HCV and HEV infections indicate low level of transmission of HEV by IDU. HEV infections warrant more attention, especially in patients with preexisting liver disease.
Authors: Anabella C Fantilli; Julieta Trinks; Sebastián Marciano; Fabián Zárate; Domingo C Balderramo; Maribel G Martínez Wassaf; Leila Haddad; Adrián Gadano; José D Debes; María B Pisano; Viviana E Ré Journal: PLoS One Date: 2019-10-24 Impact factor: 3.240
Authors: Thomas Burkard; Nora Proske; Kathrin Resner; Laura Collignon; Leonard Knegendorf; Martina Friesland; Lieven Verhoye; Ibrahim M Sayed; Yannick Brüggemann; Maximilian K Nocke; Patrick Behrendt; Heiner Wedemeyer; Philip Meuleman; Daniel Todt; Eike Steinmann Journal: Cells Date: 2022-03-08 Impact factor: 6.600
Authors: Mohammed Elhendawy; Lobna Abo-Ali; Sherief Abd-Elsalam; Maha M Hagras; Ibrahim Kabbash; Loai Mansour; Sherief Atia; Gamal Esmat; Abdel-Raouf Abo-ElAzm; Ferial El-Kalla; Abdelrahman Kobtan Journal: Environ Sci Pollut Res Int Date: 2020-06-12 Impact factor: 4.223